Activity of a new cephalosporin, CXA-101 (FR264205), against β-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 3, 2010, Pages 1213-1217

  Moya, Bartolome ^a   Zamorano, Laura ^a   Juan, Carlos ^a   Pérez, José L ^a   Ge, Yigong ^b   Oliver, Antonio ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b Calixa Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; BETA LACTAMASE AMPC; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN; CXA 101; PIPERACILLIN; QUINOLONE DERIVATIVE; TAZOBACTAM; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM MUTANT; HYDROLYSIS; IN VITRO STUDY; INTENSIVE CARE UNIT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CEPHALOSPORINS; CROSS INFECTION; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; MUTATION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 77149179342     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01104-09     Document Type: Article

References (28)

1. Aloush, V., S. Navon-Venezia, Y. Seigman-Igra, S. Cabili, and Y. Carmeli. 2006. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob. Agents Chemother. 50:43-48.
2. Carmeli, Y., N. Troillet, G. M. Eliopoulos, and M. H. Samore. 1999. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob. Agents Chemother. 43:1379-1382.
3. Cavallo, J. D., D. Hocquet, P. Plesiat, R. Fabre, and M. Roussel-Delvallez. 2007. Susceptibility of Pseudomonas aeruginosa to antimicrobials: a 2004 French multicentre hospital study. J. Antimicrob. Chemother. 59:1021-1024.
4. Deplano, A., O. Denis, L. Poirel, D. Hocquet, C. Nonhoff, B. Byl, P. Nordmann, J. L. Vincent, and M. J. Struelens. 2005. Molecular characterization of an epidemic clone of panantibiotic resistant Pseudomonas aeruginosa. J. Clin. Microbiol. 43:1198-1204.
5. El Amin, N., C. G. Giske, S. Jalal, B. Keijser, G. Kronvall, and B. Wretlind. 2005. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates. APMIS 113:187-196.
6. Giske, C. G., J. Ge, and P. Nordmann. 2009. Activity of cephalosporin CXA-101 and comparators against extended-spectrum-β- lactamase-producing Pseudomonas aeruginosa. J. Antimicrob. Chemother. 64:430-431.
7. Gutiérrez, O., C. Juan, E. Cercenado, F. Navarro, E. Bouza, P. Coll, J. L. Pérez, and A. Oliver. 2007. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. Antimicrob. Agents Chemother. 51:4329-4335.
8. Hocquet, D., P. Nordmann, F. El Garch, L. Cabanne, and P. Plésiat. 2006. Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50:1347-1351.
9. Hocquet, D., P. Berthelot, M. Roussel-Delvallez, R. Favre, K. Jeannot, O. Bajolet, N. Marty, F. Grattard, P. Mariani-Kurkdjan, E. Bingen, M. O. Housson, G. Couetdic, and P. Plesiat. 2007. Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. Antimicrob. Agents Chemother. 51:3531-3536.
10. Juan, C., O. Gutierrez, A. Oliver, J. I. Ayestarán, N. Borrell, and J. L. Pérez. 2005. Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit setting. Clin. Microbiol. Infect. 11:887-892.
11. Juan, C., M. D. Maciá, O. Gutiérrez, C. Vidal, J. L. Pérez, and A. Oliver. 2005. Molecular mechanisms of μ-lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains. Antimicrob. Agents Chemother. 49:4733-4738.
12. Juan, C., B. Moyá, J. L. Pérez, and A. Oliver. 2006. Stepwise upregulation of the Pseudomonas aeruginosa chromosomal cephalosporinase conferring high level beta-lactam resistance involves three AmpD homologues. Antimicrob. Agents Chemother. 50:1780-1787.
13. Juan, C., L. Zamorano, J. L. Pérez, Y. Ge, and A. Oliver on behalf of the Spanish Group for the Study of Pseudomonas and REIPI. 23 November 2009. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob. Agents Chemother. doi:10.1128/AAC.00834-09.
14. Leibovici, L., I. Shraga, M. Drucker, H. Konigsberger, Z. Samra, and S. D. Pitliks. 1998. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J. Intern. Med. 244:379-386.
15. Li, J., R. L. Nation, J. D. Turnidge, R. W. Milne, K. Coulthard, C. R. Rayner, and D. L. Paterson. 2006. Colistin: the re-emerging antibiotic for multidrugresistant Gram-negative bacterial infections. Lancet Infect. Dis. 6:589-601.
16. Livermore, D. M. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34:634-640.
17. Livermore, D. M., S. Mushtaq, Y. Ge, and M. Wagner. 2009. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderhia cepacia group strains and isolates. Int. J. Antimicrob. Agents 34:402-406.
18. Masuda, N., E. Sakagawa, S. Ohya, N. Gotoh, H. Tsujimoto, and T. Nishino. 2000. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXYOprM efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44:3322-3327.
19. Mesaros, N., P. Nordmann, P. Plesiat, M. Roussel-Delvallez, J. Van Eldere, Y. Glupczynski, Y. van Laethem, F. Jacobs, P. Lebesque, A. Malfroot, P. M. Tulkens, and F. van Bambeke. 2007. Pseudomonas aeruginosa: resistance and therapeutics options in the turn of the new millennium. Clin. Microbiol. Infect. 13:560-578.
20. Moya, B., A. Döstch, C. Juan, J. Blázquez, L. Zamorano, S. Haussler, and A. Oliver. 2009. β-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein. PloS Pathog. 5:e1000353.
21. Mushtaq, S., Y. Ge, and D. M. Livermore. 2004. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob. Agents Chemother. 48:3086-3092.
22. Obritsch, M. D., D. N. Fish, R. MacLaren, and R. Jung. 2004. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob. Agents Chemother. 48:4606-4610.
23. Peña, C., C. Súarez, F. Tubau, C. Juan, B. Moya, M. A. Domínguez, A. Oliver, M. Pujol, and J. Ariza. 3 June 2009. Nosocomial outbreak of a cefepime-nonsusceptible ceftazidime-susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 β-lactamase. J. Clin. Microbiol. doi:10.1128/JCM.00094-09.
24. Pirnay, J. P., D. de Vos, D. Mossialos, A. Vanderkelen, P. Cornelis, and M. Zizi. 2002. Analysis of the Pseudomonas aeruginosa oprD gene from clinical and environmental isolates. Environ. Microbiol. 4:872-882.
25. Poole, K. 2004. Efflux-mediated multiresistance in Gram-negative bacteria. Clin. Microbiol. Infect. 10:12-26.
26. Quale, J., S. Bratu, J. Gupta, and D. Landman. 2006. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 50:1633-1641.
27. Takeda, S., Y. Ishii, K. Hatano, K. Tateda, and K. Yamaguchi. 2007. Stability of FR264205 against AmpC β-lactamase of Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 30:443-445.
28. Takeda, S., T. Nakai, Y. Wakai, F. Ikeda, and K. Hatano. 2007. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 51:826-830.